The 1st patient has been dosed in the P-I/II study in which the P-I dose escalation study evaluates the safety of GDA-201 in patients with FL, DLBCL/HGBL, MZL & MCL whereas the P-II expansion study evaluates the safety & efficacy of GDA-201 in patients (n=63) divided into two groups with either FL or DLBCL
Earlier, the results from an investor-sponsored P-I/II study evaluating GDA-201 + rituximab in patients (n=19) with NHL showed a complete (n=13) & partial response (n=1) in patients along with an OR of 74%, CRR of 68%, mDoR of 16mos. & an OS at 2yrs of 78%
GDA-201 is an innate NK cell immunotherapy developed by using Gamida’s NAM-enabled cell expansion technology for the treatment of hematologic & solid tumors
Ref: Businesswire | Image: Gamida Cell
